Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Selecta BiosciencesUroGen PharmaBioDelivery Sciences InternationalAthersysPuma Biotechnology
SymbolNASDAQ:SELBNASDAQ:URGNNASDAQ:BDSINASDAQ:ATHXNASDAQ:PBYI
Price Information
Current Price$3.87$18.35$3.42$1.69$10.07
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.61.82.11.31.4
Analysis Score3.43.53.43.52.0
Community Score2.23.03.02.62.5
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.70.01.7
Earnings & Valuation Score0.60.62.50.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$7.20$37.33$8.15$9.00$12.50
% Upside from Price Target86.05% upside103.45% upside138.30% upside432.54% upside24.13% upside
Trade Information
Market Cap$434.88 million$383.46 million$344.95 million$363.76 million$405.40 million
Beta1.181.320.72-1.541.39
Average Volume1,746,185205,0771,245,2393,102,071377,869
Sales & Book Value
Annual Revenue$6.68 million$20,000.00$111.39 million$5.63 million$272.30 million
Price / Sales65.1019,173.003.1064.611.49
CashflowN/AN/A$0.14 per shareN/AN/A
Price / CashN/AN/A24.16N/AN/A
Book Value$0.10 per share$8.63 per share$0.78 per share$0.15 per share$0.45 per share
Price / Book38.702.134.3811.2722.38
Profitability
Net Income$-55,350,000.00$-105,150,000.00$-15,310,000.00$-44,580,000.00$-75,600,000.00
EPS($1.22)($5.12)$0.10($0.29)($1.95)
Trailing P/E RatioN/AN/A24.43N/AN/A
Forward P/E RatioN/AN/A9.00N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A10.16%N/A-23.86%
Return on Equity (ROE)N/A-92.22%25.04%-176.56%-451.50%
Return on Assets (ROA)-54.69%-81.71%9.89%-112.67%-22.80%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/A0.82%N/A4.13%
Current Ratio2.16%7.34%3.16%3.32%1.35%
Quick Ratio2.16%7.26%2.80%3.32%1.33%
Ownership Information
Institutional Ownership Percentage56.92%71.60%67.40%27.87%87.90%
Insider Ownership Percentage22.40%12.00%8.57%12.60%21.20%
Miscellaneous
Employees4318717683267
Shares Outstanding112.37 million20.90 million100.86 million215.25 million40.26 million
Next Earnings Date5/6/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Confirmed)5/6/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Puma Biotechnology, Inc. (NASDAQ:PBYI) Expected to Announce Quarterly Sales of $74.82 MillionPuma Biotechnology, Inc. (NASDAQ:PBYI) Expected to Announce Quarterly Sales of $74.82 Million
americanbankingnews.com - April 7 at 4:44 AM
Puma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach Sells 1,584 SharesPuma Biotechnology, Inc. (NASDAQ:PBYI) CEO Alan H. Auerbach Sells 1,584 Shares
americanbankingnews.com - April 6 at 7:38 PM
Puma Biotechnology, Inc. (NASDAQ:PBYI) Given Average Rating of "Hold" by BrokeragesPuma Biotechnology, Inc. (NASDAQ:PBYI) Given Average Rating of "Hold" by Brokerages
americanbankingnews.com - April 6 at 6:40 AM
Zacks: Analysts Expect Puma Biotechnology, Inc. (NASDAQ:PBYI) Will Post Earnings of $0.33 Per ShareZacks: Analysts Expect Puma Biotechnology, Inc. (NASDAQ:PBYI) Will Post Earnings of $0.33 Per Share
americanbankingnews.com - April 5 at 2:12 AM
Puma Biotechnology, Inc. (NASDAQ:PBYI) Expected to Post Earnings of $0.33 Per SharePuma Biotechnology, Inc. (NASDAQ:PBYI) Expected to Post Earnings of $0.33 Per Share
americanbankingnews.com - April 5 at 2:12 AM
Puma Biotech (PBYI) Down 6.3% Since Last Earnings Report: Can It Rebound?Puma Biotech (PBYI) Down 6.3% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - March 27 at 12:32 PM
Puma Biotechnology to Present at the Barclays Global Healthcare ConferencePuma Biotechnology to Present at the Barclays Global Healthcare Conference
finance.yahoo.com - March 4 at 7:53 PM
Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences ConferencePuma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 6:51 PM
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle ArbitrationCANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration
finance.yahoo.com - February 25 at 6:41 PM
Puma Biotech: 4Q Earnings Snapshot | Raleigh News & ObserverPuma Biotech: 4Q Earnings Snapshot | Raleigh News & Observer
newsobserver.com - February 25 at 6:41 PM
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial ResultsPuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 11 at 8:08 PM
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung CancePuma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cance
us.acrofan.com - January 29 at 1:03 PM
Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020Puma Biotechnology Presents Interim Results from the Phase II SUMMIT Trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020
finance.yahoo.com - January 29 at 1:03 PM
Puma Biotechnologys (NASDAQ:PBYI) Shareholders Are Down 82% On Their SharesPuma Biotechnology's (NASDAQ:PBYI) Shareholders Are Down 82% On Their Shares
finance.yahoo.com - January 26 at 2:07 PM
Puma Biotechnology to Present at the B. Riley Oncology Investor ConferencePuma Biotechnology to Present at the B. Riley Oncology Investor Conference
finance.yahoo.com - January 19 at 6:44 PM
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GIPuma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT “Basket” Trial of Neratinib at ASCO GI
businesswire.com - January 15 at 5:24 PM
Puma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT "Basket" Trial of Neratinib at ASCO GIPuma Biotechnology Presents Interim Results from the Biliary Tract Cancers Cohort of the Phase II SUMMIT "Basket" Trial of Neratinib at ASCO GI
finance.yahoo.com - January 15 at 5:24 PM
ONK Therapeutics Appoints Hugh O’Dowd as Independent ChairmanONK Therapeutics Appoints Hugh O’Dowd as Independent Chairman
apnews.com - January 14 at 5:07 AM
Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect ConferencePuma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
finance.yahoo.com - January 4 at 6:36 PM
PBYI Dec 2020 7.500 callPBYI Dec 2020 7.500 call
ca.finance.yahoo.com - December 24 at 12:29 AM
PBYI Dec 2020 15.000 putPBYI Dec 2020 15.000 put
ca.finance.yahoo.com - December 24 at 12:29 AM
Is PBYI A Good Stock To Buy Now?Is PBYI A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 7:49 PM
Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCSPuma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA Trial at the 2020 SABCS
finance.yahoo.com - December 11 at 2:37 PM
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCSPuma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS
us.acrofan.com - December 9 at 9:34 PM
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020
finance.yahoo.com - December 9 at 9:34 PM
DateCompanyBrokerageAction
3/18/2021Selecta BiosciencesWilliam BlairUpgrade
1/26/2021Selecta BiosciencesMizuhoUpgrade
1/7/2021Selecta BiosciencesCanaccord GenuityReiterated Rating
1/7/2021Selecta BiosciencesHC WainwrightReiterated Rating
10/9/2020Selecta BiosciencesCantor FitzgeraldReiterated Rating
6/18/2020Selecta BiosciencesStifel NicolausReiterated Rating
6/18/2020Selecta BiosciencesNeedham & Company LLCReiterated Rating
11/10/2020UroGen PharmaOppenheimerLower Price Target
9/21/2020UroGen PharmaJPMorgan Chase & Co.Lower Price Target
1/16/2020UroGen PharmaCowenReiterated Rating
1/9/2020UroGen PharmaNational SecuritiesInitiated Coverage
5/25/2020BioDelivery Sciences InternationalPiper SandlerReiterated Rating
5/25/2020BioDelivery Sciences InternationalRoth CapitalReiterated Rating
4/22/2020BioDelivery Sciences InternationalNorthland SecuritiesInitiated Coverage
12/18/2019BioDelivery Sciences InternationalSunTrust BanksBoost Price Target
11/13/2019BioDelivery Sciences InternationalLADENBURG THALM/SH SHBoost Price Target
11/13/2019BioDelivery Sciences InternationalJanney Montgomery ScottReiterated Rating
10/12/2020AthersysDawson JamesReiterated Rating
6/25/2020AthersysBank of AmericaInitiated Coverage
4/23/2020AthersysSmith Barney CitigroupInitiated Coverage
5/9/2019AthersysMaxim GroupReiterated Rating
8/10/2020Puma BiotechnologyCitigroupLower Price Target
8/7/2020Puma BiotechnologySVB LeerinkLower Price Target
5/10/2020Puma BiotechnologyRoyal Bank of CanadaReiterated Rating
1/3/2020Puma BiotechnologyGuggenheimDowngrade
11/7/2019Puma BiotechnologyBarclaysLower Price Target
10/8/2019Puma BiotechnologyThe Goldman Sachs GroupDowngrade
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.